Clinical Trials Logo

Prenatal Disorder clinical trials

View clinical trials related to Prenatal Disorder.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03898440 Completed - Prenatal Disorder Clinical Trials

Fetal Ano-genital Distance in 2D Ultrasound.

DAG
Start date: April 15, 2019
Phase:
Study type: Observational

The purpose of this study is to determine a threshold value of fetal anogenital distance in 2D ultrasound to differentiate male fetuses from female fetuses, starting 18 weeks of gestation and until the due date. The study also evaluates the feasibility of the measure and its interobserver variability.

NCT ID: NCT03715036 Completed - Prenatal Disorder Clinical Trials

Point of Care Ultrasound Screening for Abnormal Fetal Growth During Routine Antenatal Visits

Start date: April 29, 2019
Phase: N/A
Study type: Interventional

Abdominal circumference (AC) in the fetus is the single most useful indicator of fetal growth abnormalities. Measurement of AC as well as DVP do not require extensive training. Our objective is to evaluate if introduction of bedside ultrasound during routine antenatal visits to evaluate fetal AC and amniotic fluid DVP would decrease the false positive rates of fundal height measurement in diagnosing intrauterine growth abnormalities.

NCT ID: NCT03441672 Completed - Prenatal Disorder Clinical Trials

Game-Based Decision Aid to Educate Pregnant Women About Prenatal Screening

Start date: November 1, 2016
Phase: N/A
Study type: Interventional

Significant barriers exist for effectively informing women about prenatal screening in the clinical setting. This project developed and evaluated the efficacy of a game decision aid among pregnant women about prenatal screening in a randomized controlled study.

NCT ID: NCT03420274 Completed - Clinical trials for Pregnancy Complications

Ensuring Patients' Informed Access to Noninvasive Prenatal Testing

NEST
Start date: February 19, 2018
Phase: N/A
Study type: Interventional

Noninvasive prenatal genetic testing (NIPT) is an important new screening test option provided to pregnant women in the first trimester of pregnancy. The advantage of this screen is that is provides information about the risk of trisomy 13, trisomy 18, and trisomy 21 with greater accuracy than conventional screens. At the same time, NIPT can produce information about the risk of a cohort of other fetal genetic variants, including sex chromosome aneuploidies and microdeletion syndromes. While not yet clinically available for whole exome sequencing, the potential for this next clinical application already exists. The challenge is that, while this is an important new test, there are little data about how to best structure patient-centered decisions about its use, including decisions if to use this screen and how the information may directly inform subsequent prenatal care decisions. The purpose of this study is to gain formative data about current practice patterns with respect to how NIPT is discussed in the clinical visit and to use these data to help inform best practices for its continued use in the clinical setting.